Gene mutations of acute myeloid leukemia in the genome era

[1]  Julia C. Engelmann,et al.  Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing. , 2012, Blood.

[2]  A. Jankowska,et al.  SF3B1 haploinsufficiency leads to formation of ring sideroblasts in myelodysplastic syndromes. , 2012, Blood.

[3]  A. Kohlmann,et al.  A novel hierarchical prognostic model of AML solely based on molecular mutations. , 2012, Blood.

[4]  Seishi Ogawa,et al.  Splicing factor mutations in myelodysplasia , 2012, International Journal of Hematology.

[5]  O. Abdel-Wahab,et al.  The role of mutations in epigenetic regulators in myeloid malignancies , 2012, Nature Reviews Cancer.

[6]  Iannis Aifantis,et al.  ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. , 2012, Cancer cell.

[7]  S. Sugano,et al.  Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. , 2012, Blood.

[8]  Joshua F. McMichael,et al.  The Origin and Evolution of Mutations in Acute Myeloid Leukemia , 2012, Cell.

[9]  Claude Preudhomme,et al.  Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. , 2012, Blood.

[10]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[11]  D. Birnbaum,et al.  Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases , 2012, Journal of Hematology & Oncology.

[12]  Ken Chen,et al.  Clonal architecture of secondary acute myeloid leukemia. , 2012, The New England journal of medicine.

[13]  W. Sperr,et al.  Frequency, onset and clinical impact of somatic DNMT3A mutations in therapy-related and secondary acute myeloid leukemia , 2012, Haematologica.

[14]  Y. Assaraf,et al.  The role of minor subpopulations within the leukemic blast compartment of AML patients at initial diagnosis in the development of relapse , 2012, Leukemia.

[15]  Joshua F. McMichael,et al.  Clonal evolution in relapsed acute myeloid leukemia revealed by whole genome sequencing , 2011, Nature.

[16]  J. Berg,et al.  Dnmt3a is essential for hematopoietic stem cell differentiation , 2011, Nature Genetics.

[17]  Verena I Gaidzik,et al.  TET2 mutations in acute myeloid leukemia (AML): results from a comprehensive genetic and clinical analysis of the AML study group. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  M. Caligiuri,et al.  ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. , 2011, Blood.

[19]  L. Pasqualucci,et al.  Whole-exome sequencing identifies somatic mutations of BCOR in acute myeloid leukemia with normal karyotype. , 2011, Blood.

[20]  K. Kinzler,et al.  Somatic mutations in the transcriptional corepressor gene BCORL1 in adult acute myelogenous leukemia. , 2011, Blood.

[21]  Chieh-Yu Liu,et al.  Clinical Trials and Observations , 2022 .

[22]  Jean-François Millau,et al.  CTCF, cohesin, and histone variants: connecting the genome. , 2011, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[23]  M. McDevitt,et al.  Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes , 2011, Haematologica.

[24]  Yang Wang,et al.  Tet-Mediated Formation of 5-Carboxylcytosine and Its Excision by TDG in Mammalian DNA , 2011, Science.

[25]  I. Kitabayashi,et al.  Deregulated transcription factors in leukemia , 2011, International journal of hematology.

[26]  K. Wagner,et al.  Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  O. Abdel-Wahab,et al.  Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. , 2011, Cancer cell.

[28]  D. Neuberg,et al.  Clinical effect of point mutations in myelodysplastic syndromes. , 2011, The New England journal of medicine.

[29]  G. Ming,et al.  Hydroxylation of 5-Methylcytosine by TET1 Promotes Active DNA Demethylation in the Adult Brain , 2011, Cell.

[30]  W. Reik,et al.  Dynamic regulation of 5-hydroxymethylcytosine in mouse ES cells and during differentiation , 2011, Nature.

[31]  Verena I Gaidzik,et al.  RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  M. Caligiuri,et al.  TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  Keji Zhao,et al.  Genome-wide analysis of 5-hydroxymethylcytosine distribution reveals its dual function in transcriptional regulation in mouse embryonic stem cells. , 2011, Genes & development.

[34]  J. Licht,et al.  DNMT3A mutations in acute myeloid leukemia , 2011, Nature Genetics.

[35]  Yong-mei Zhu,et al.  Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia , 2011, Nature Genetics.

[36]  Torsten Haferlach,et al.  Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  D. Reinberg,et al.  The Polycomb complex PRC2 and its mark in life , 2011, Nature.

[38]  D. Gilliland,et al.  Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms , 2010, Leukemia.

[39]  F. Chédin.  The DNMT3 family of mammalian de novo DNA methyltransferases. , 2011, Progress in molecular biology and translational science.

[40]  A. Losada,et al.  Cohesin ties up the genome. , 2010, Current opinion in cell biology.

[41]  B. Ko,et al.  Distinct clinical and biological features of de novo acute myeloid leukemia with additional sex comb-like 1 (ASXL1) mutations. , 2010, Blood.

[42]  L. Aravind,et al.  Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2 , 2010, Nature.

[43]  Y. Assaraf,et al.  High-frequency type I/II mutational shifts between diagnosis and relapse are associated with outcome in pediatric AML: implications for personalized medicine. , 2010, Blood.

[44]  S. Su,et al.  IDH mutations in glioma and acute myeloid leukemia. , 2010, Trends in molecular medicine.

[45]  Manuela Zucknick,et al.  IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  H. Drexler,et al.  Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders , 2010, Nature Genetics.

[47]  R. Kuiper,et al.  Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes , 2010, Nature Genetics.

[48]  Michael Heuser,et al.  Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. , 2010, Blood.

[49]  R. Hills,et al.  Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. , 2010, Blood.

[50]  M. Caligiuri,et al.  IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  K. Wagner,et al.  Impact of IDH1 R132 mutations and an IDH1 single nucleotide polymorphism in cytogenetically normal acute myeloid leukemia: SNP rs11554137 is an adverse prognostic factor. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  Omar Abdel-Wahab,et al.  The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. , 2010, Cancer cell.

[53]  Bob Löwenberg,et al.  Review Articles (434 articles) , 2008 .

[54]  J. Hess,et al.  Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia. , 2010, Blood.

[55]  Chieh-Yu Liu,et al.  AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. , 2009, Blood.

[56]  L. Liau,et al.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate , 2009, Nature.

[57]  J. Soulier,et al.  Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.

[58]  Ken Chen,et al.  Recurring mutations found by sequencing an acute myeloid leukemia genome. , 2009, The New England journal of medicine.

[59]  D. Gilliland,et al.  Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. , 2009, Blood.

[60]  A. Hagemeijer,et al.  Acquired mutations in TET2 are common in myelodysplastic syndromes , 2009, Nature Genetics.

[61]  David R. Liu,et al.  Conversion of 5-Methylcytosine to 5- Hydroxymethylcytosine in Mammalian DNA by the MLL Partner TET1 , 2009 .

[62]  Kun-Liang Guan,et al.  Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α , 2009, Science.

[63]  Bas J. Wouters,et al.  Brief Report Results and Discussion , 2022 .

[64]  Daniel G Tenen,et al.  Dysregulation of the C/EBPalpha differentiation pathway in human cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[65]  B. Löwenberg,et al.  profile that is uniquely associated with a favorable outcome subgroup of acute myeloid leukemia with a distinctive gene expression mutations, define a CEBPA mutations, but not single CEBPA Double , 2009 .

[66]  C. Allis,et al.  DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA , 2007, Nature.

[67]  A. Spurdle,et al.  A Novel Corepressor, BCoR-L1, Represses Transcription through an Interaction with CtBP* , 2007, Journal of Biological Chemistry.

[68]  Hideo Ema,et al.  De novo DNA methyltransferase is essential for self-renewal, but not for differentiation, in hematopoietic stem cells , 2007, The Journal of experimental medicine.

[69]  Q. Waisfisz,et al.  Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples , 2006, Leukemia.

[70]  T. Naoe,et al.  Biology, Clinical Relevance, and Molecularly Targeted Therapy in Acute Leukemia with Flt3 Mutation , 2006, International journal of hematology.

[71]  G. Marcucci.  Core binding factor acute myeloid leukemia. , 2006, Clinical advances in hematology & oncology : H&O.

[72]  T. Brümmendorf,et al.  Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. , 2004, Blood.

[73]  T. Naoe,et al.  Clinical characteristics and prognostic implications of NPM1 mutations in acute myeloid leukemia. , 2005, Blood.

[74]  S. Fröhling,et al.  Genetics of myeloid malignancies: pathogenetic and clinical implications. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  Guoqiang Chen,et al.  AML1-ETO and C-KIT mutation/overexpression in t(8;21) leukemia: implication in stepwise leukemogenesis and response to Gleevec. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[76]  Paola Fazi,et al.  Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.

[77]  L. Peterson,et al.  The 8;21 translocation in leukemogenesis , 2004, Oncogene.

[78]  J. Radich,et al.  The role of FLT3 in haematopoietic malignancies , 2003, Nature Reviews Cancer.

[79]  J. Reilly,et al.  Incidence and prognosis of c‐KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias , 2003, British journal of haematology.

[80]  B. Chait,et al.  Ezh2 controls B cell development through histone H3 methylation and Igh rearrangement , 2003, Nature Immunology.

[81]  S. Dhanasekaran,et al.  The polycomb group protein EZH2 is involved in progression of prostate cancer , 2002, Nature.

[82]  D. Gilliland,et al.  Core-binding factors in haematopoiesis and leukaemia , 2002, Nature Reviews Cancer.

[83]  T. Ley,et al.  PML/RARα and FLT3-ITD induce an APL-like disease in a mouse model , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[84]  T. Naoe,et al.  FLT3 in Human Hematologic Malignancies , 2002, Leukemia & lymphoma.

[85]  T. Ley,et al.  PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[86]  D. Gilliland,et al.  FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. , 2002, Blood.

[87]  T. Naoe,et al.  Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. , 2001, Blood.

[88]  P. Peterlongo,et al.  C-kit mutations in core binding factor leukemias. , 2000, Blood.

[89]  U. Thorsteinsdóttir,et al.  Functional antagonism of the Polycomb-Group genes eed and Bmi1 in hemopoietic cell proliferation. , 1999, Genes & development.

[90]  T. Naoe,et al.  Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. , 1999, Blood.

[91]  T. Naoe,et al.  Molecular evolution of acute myeloid leukaemia in relapse: unstable N‐ras and FLT3 genes compared with p53 gene , 1999, British journal of haematology.

[92]  M. Kyba,et al.  The Additional sex combs gene of Drosophila encodes a chromatin protein that binds to shared and unique Polycomb group sites on polytene chromosomes. , 1998, Development.

[93]  H. Kaneko,et al.  Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. , 1996, Leukemia.

[94]  C. Bloomfield,et al.  Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. , 1994, Blood.

[95]  J. Radich,et al.  N-ras mutations in adult de novo acute myelogenous leukemia: prevalence and clinical significance. , 1990, Blood.